SOURCE: Elsevier Business Systems

Elsevier Business Systems

September 01, 2009 09:00 ET

Influential Medtech VCs Will Disclose Investing Trends at Elsevier Business Intelligence's 'IN3 Medical Device Summit' in San Francisco, October 20-21

'IN3 Summit' Follows Elsevier Business Intelligence's 'Medical Device Investor Day' in San Francisco on October 19

SAN FRANCISCO, CA--(Marketwire - September 1, 2009) - Elsevier Business Intelligence, the medtech industry's leading strategic partner and investment conference organizer, announced today that it will host the largest annual strategic partnership and investment meeting, 'IN3 Medical Device Summit', on October 20-21 at San Francisco's InterContinental Mark Hopkins Hotel. This event follows Elsevier Business Intelligence's 'Medical Device Investor Day', also being held at the InterContinental Mark Hopkins, on October 19.

IN3 Medical Device Summit is the largest annual strategic partnership and investment meeting for senior-level medical technology executives. Hundreds of venture capital firms and medical technology companies are expected to attend IN3 Medical Device Summit on October 20 and 21 to hear about the latest innovations and investment opportunities from more than 50 emerging medical technology companies seeking funding and/or strategic partnerships.

Medical Device Investor Day is a unique event for medical technology executives who are interested in what the leaders of the industry are thinking, doing, and planning in terms of investment. Senior execs from large medtech multinationals such as Medtronic and Becton Dickinson, along with managing directors from leading VC firms with a device focus such as Ascension Health Ventures, MedVenture Associates, New Leaf Venture Partners, Saints Capital and Versant Ventures, will speak candidly about what interests them most in the medtech space today.

"The macro economic environment presents numerous opportunities for investors and entrepreneurs," said Sami Hamade, Partner, Aberdare Ventures. "For example, as the nation debates public policy and healthcare, one thing for certain is that expenses for healthcare are going to go up in the short term, not down, as we bring 40-plus million Americans into the system. It's upon us, entrepreneurs and investors, to find solutions that not only will make the deployment of cash more effective but also improve patient outcomes -- and that approach will continue to open up opportunities for the medtech industry," added Hamade, who will participate as a panelist during IN3 Medical Device Summit on October 20-21.

For more information about Medical Device Investor Day and IN3 Medical Device Summit, visit www.meddevicesummit.com or contact Kristy Grimes at 480-985-9512, 888-290-2225 (U.S. toll-free), or email k.grimes@elsevier.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as Science Direct (www.sciencedirect.com), MDConsult (www.mdconsult.com), Nursing Consult (www.nursingconsult.com), Scopus (www.info.scopus.com), bibliographic databases, and online reference works.

Elsevier (www.elsevier.com) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (www.reedelsevier.com), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information

  • Contact:
    Ronald Trahan, APR
    Ronald Trahan Associates Inc.
    508-359-4005, x108